NanoViricides, Inc. — Form 10-Q summary
Reporting period: Three months ended September 30, 2023 (the company’s first quarter of fiscal 2024); filed November 14, 2023. The company is a clinical-stage antiviral drug developer with no commercial products or revenue.
Financial performance and position
| Metric | Quarter ended Sep. 30, 2023 | Prior-year quarter / comparison |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $1.467 million | $1.113 million; up $354,006 |
| General and administrative expense | $565,000 | $510,000; up $55,225 |
| Total operating expenses / operating loss | $2.032 million | $1.622 million |
| Interest income / expense | $99,338 / $36,493 | $52,562 / $844 |
| Net loss | $1.969 million; $0.17 per share | $1.571 million; $0.14 per share |
| Operating cash used | $1.172 million | $1.033 million |
| Cash and cash equivalents at period end | $6.970 million | $8.150 million at June 30, 2023 |
| Total assets / total liabilities | $15.417 million / $2.448 million | $16.900 million / $2.034 million at June 30, 2023 |
| Stockholders’ equity | $12.969 million | $14.866 million at June 30, 2023 |
No operating profit or margins were reported because the company had no revenue. Accumulated deficit was $133.049 million. Net property and equipment was $7.928 million. Current liabilities were $948,311; the company also reported a $1.5 million related-party convertible note as a non-current liability at quarter end.
Material changes and developments
- Net loss rose by $398,104 year over year, primarily reflecting higher R&D and professional-fee costs. R&D expense included increased clinical-development costs and laboratory fees.
- Cash declined by $1.180 million during the quarter. Investing cash outflow was $8,291; there was no financing cash flow in the quarter.
- The $1.5 million milestone obligation to related party TheraCour was documented as a 12% convertible note in July 2023, resulting in $36,493 of accrued interest through September 30. On October 27, TheraCour converted principal into 331,859 Series A preferred shares and cancelled all accrued interest.
- After quarter end, CEO Anil Diwan agreed to provide a standby credit line of up to $2 million at 12% interest, secured by company real property and equipment. Draws require board approval; management said it did not anticipate borrowing in the current fiscal year.
- Common shares outstanding were 11,745,547 at September 30, versus 11,698,497 at June 30. Subsequent note conversion increased Series A preferred shares; those shares are convertible into common stock only upon a change of control.
Outlook, clinical programs, and risks
- Management said available cash and the standby credit line were expected to support planned operations for at least 12 months from filing. The company has no revenue and expects continuing losses; additional capital will be needed for longer-term operations and later-stage trials. Financing, grants, partnerships, and licensing are possible sources, but none is assured.
- The lead candidate, NV-CoV-2 (active ingredient NV-387), was in Phase 1a/1b trials in India sponsored by Karveer. As reported in August, 26 of 36 expected participants had completed each of the single- and multiple-ascending-dose portions; no adverse events or serious adverse events had been reported to date. The company expects trial results to inform potential further development, including for RSV, subject to results and regulatory approvals.
- The company reported preclinical NV-387 effectiveness against RSV. On November 14, after the quarter, it also reported results from an ongoing lethal mouse model of ectromelia infection, describing NV-387 as comparable to tecovirimat and a longer survival result for combination treatment. These are company-reported animal-model findings, not clinical efficacy evidence.
- Management’s plans include pursuing COVID and RSV development, seeking non-dilutive funding for poxvirus work, and advancing shingles and other programs as resources permit. Trial costs, timelines, regulatory requirements, and development budgets may exceed estimates; management noted limited experience conducting human trials.
- The company relies on TheraCour, an entity controlled by CEO and significant stockholder Anil Diwan, for licensed technology and development work. The agreement provides for cost-based charges and, upon commercialization, 15% of net sales. Karveer, the India licensee and trial sponsor, is also related through Diwan’s passive investment and advisory role. The company pays Karveer trial costs plus a 30% management fee and would receive 70% of qualifying sales in India.
- Disclosure controls were deemed ineffective at September 30 because of a previously reported material weakness, which management said was not fully remediated for timeliness. The company reported no pending or threatened legal proceedings believed likely to have a material adverse effect.
Investor verification points
- Check subsequent disclosures for completion, safety findings, and results of the Phase 1a/1b trial, and for any regulatory plans or approvals for COVID or RSV.
- Verify cash burn, actual use and terms of the CEO credit line, and the company’s funding runway as trial spending evolves.
- Review the accounting and potential dilution associated with the preferred-share note conversion, employee awards, and other related-party transactions.
- Assess progress in remediating the material weakness and improving the timeliness of financial reporting.
- Distinguish company-reported preclinical findings and forward-looking development plans from demonstrated human efficacy, approvals, or commercial revenue.